Allergy Territory Account Specialist

Quote

anonymous said:
Dupilumab is now approved by the FDA in chronic urticaria. In the press 300.000 patients alone in the US are mentioned as market potential.
Click to expand...
If you went through disease state training recently, you would have see that Novartis says there are 400,000 patients being untreated or under treated. That’s a big difference
 


Roche presented Xolair data, 26% growth, 50000 NRX patients, no biosimilar expected 2025, great opportunity for Remibrutinib achieving Blockbuster Status in the US in 2 years after launch
 


anonymous said:
Roche presented Xolair data, 26% growth, 50000 NRX patients, no biosimilar expected 2025, great opportunity for Remibrutinib achieving Blockbuster Status in the US in 2 years after launch
Click to expand...
Wrong. March 7 a biosimilar was approved in the US - made by a company called Celltrion. With a Xolair biosimilar, the recent Dupixent approval and Novartis lack of contracting for formulary placement, I doubt Remi will have the launch the company expects
 


anonymous said:
Wrong. March 7 a biosimilar was approved in the US - made by a company called Celltrion. With a Xolair biosimilar, the recent Dupixent approval and Novartis lack of contracting for formulary placement, I doubt Remi will have the launch the company expects
Click to expand...
Dupixent CSU data isn’t impressing anyone, Remi for the win
 


anonymous said:
Dupixent CSU data isn’t impressing anyone, Remi for the win
Click to expand...
Do you really think only the data is what’s going to get the business? Allergists and dermatologists write dupixent like water. It’s easy for them to get and they have been using off label for years now for hives. Combine with the fact that csu often comes along with atopic dermatitis, and it’s a no brainer for these providers. Sanofi/regeneron have specialty pharmacies they work with that do the prior authorizations for offices as well. Dupixent isn’t the end all drug, but it will work for csu or it wouldn’t be approved.
 


anonymous said:
Do you really think only the data is what’s going to get the business? Allergists and dermatologists write dupixent like water. It’s easy for them to get and they have been using off label for years now for hives. Combine with the fact that csu often comes along with atopic dermatitis, and it’s a no brainer for these providers. Sanofi/regeneron have specialty pharmacies they work with that do the prior authorizations for offices as well. Dupixent isn’t the end all drug, but it will work for csu or it wouldn’t be approved.
Click to expand...
I get it, Dupixent has a name and an army of reps with the aforementioned PA help, but it’s our job as reps to show them Remis data and yes, in many cases compare to the inferiority of Dupixents data. “Dr, Dupixent is a great medication, but it’s not the right choice for CSU, let me show you why that is.”
 


You people and Novartis seem to forget that Xolair works fantastic in CSU and will remain the primary choice in the market. The remi efficacy data is okay but not blockbuster material. Good luck to all!
 


anonymous said:
I get it, Dupixent has a name and an army of reps with the aforementioned PA help, but it’s our job as reps to show them Remis data and yes, in many cases compare to the inferiority of Dupixents data. “Dr, Dupixent is a great medication, but it’s not the right choice for CSU, let me show you why that is.”
Click to expand...
Ok rep / what’s your formulary coverage for Remi? If it’s not covered without any step through beside antihistamines, it’s not getting written. Unless the company gives away free drug at first. But ask the leqvio reps about that debacle….
 


anonymous said:
I get it, Dupixent has a name and an army of reps with the aforementioned PA help, but it’s our job as reps to show them Remis data and yes, in many cases compare to the inferiority of Dupixents data. “Dr, Dupixent is a great medication, but it’s not the right choice for CSU, let me show you why that is.”
Click to expand...
Save the Homer company crap ya douche bag
 












anonymous said:
Ok Homer / what’s your formulary coverage for Remi? If it’s not covered without any step through beside antihistamines, it’s not getting written. Unless the company gives away free drug at first. But ask the leqvio reps about that debacle….
Click to expand...
I hope your were able to find another job, laid off CV rep
 






anonymous said:
Ok Homer / what’s your formulary coverage for Remi? If it’s not covered without any step through beside antihistamines, it’s not getting written. Unless the company gives away free drug at first. But ask the leqvio reps about that debacle….
Click to expand...
Remi is another Novartis launch disaster waiting to happen.
 


anonymous said:
Ok Homer / what’s your formulary coverage for Remi? If it’s not covered without any step through beside antihistamines, it’s not getting written. Unless the company gives away free drug at first. But ask the leqvio reps about that debacle….
Click to expand...
I heard Remi wont have huge obstacles for coverage due to efficacy safety and being a pill. We still have no clue what coverage is like until its approved, so why be so negative ?
 


anonymous said:
I heard Remi wont have huge obstacles for coverage due to efficacy safety and being a pill. We still have no clue what coverage is like until its approved, so why be so negative ?
Click to expand...
Go to urticariaknowledgecenter.com and compare the latest Omalizumab data with Remi. Anyway, manufacturing issues are knocking on the door and we have to be patient until we see realised sales.
 



Write your reply...
Top Bottom
Back
Quote